Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has said that its research and diagnostic antibodies unit, AbD Serotec will expand its sales organization in Dusseldorf to support growth in continental and eastern Europe as well as in Asia.
Subscribe to our email newsletter
The official opening ceremony was performed by Friedrich Conzen, major of Dusseldorf. Dr Simon Moroney, chief executive officer of MorphoSys Group, also attended along with Dieter Feger, Head of AbD Serotec. The expanded Dusseldorf office will coordinate global sales activities of AbD Serotec outside North, Central and South America.
Dieter Feger, head of AbD Serotec, said: “While we expect demand in our traditional markets to remain solid, we have identified new areas of growth potential, and are now planning to expand our sales outreach to increase our market share in eastern Europe and Asia, as well as in our core market here in western Europe. Our plans to add a telemarketing sales force and expand our direct marketing efforts will act as central components of our growth strategy in these markets.”
According to MorphoSys’s financial guidance, AbD Serotec is expected to contribute roughly one quarter of total group revenues in 2009, driven by above-market growth rates, with an operating profit margin of up to 6%. MorphoSys expects the segment’s financial performance to improve further in 2010.